Nucala

(Mepolizumab)

Nucala

Drug updated on 11/10/2023

Dosage FormInjection (subcutaneous; 100 mg, 100 mg/mL, 40 mg/0.4 mL)
Drug ClassInterleukin-5 antagonist monoclonal antibodies
Ongoing and Completed StudiesClinicalTrials.gov

Indication

  • Indicated for add-on maintenance treatment of adult and pediatric patients aged 6 years and older with severe asthma and with an eosinophilic phenotype.
  • Indicated for add-on maintenance treatment of adult patients 18 years and older with chronic rhinosinusitis with nasal polyps (CRSwNP).
  • For the treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA).
  • For the treatment of adult and pediatric patients aged 12 years and older with hypereosinophilic syndrome (HES) for ≥6 months without an identifiable non-hematologic secondary cause.

Product Monograph / Prescribing Information

Document TitleYearSource
Nucala (mepolizumab) Prescribing Information.2022GlaxoSmithKline LLC, Philadelphia, PA

Systematic Reviews / Meta-Analyses

Document TitleYearSource
Clinical, pharmacoeconomic, and stakeholder input combined report.2023CADTH
Incidence of anti-drug antibodies to monoclonal antibodies in asthma: a systematic review and meta-analysis.2023The Journal of Allergy and Clinical Immunology: In Practice
Comparative efficacy of tezepelumab to mepolizumab, benralizumab, and dupilumab in eosinophilic asthma: A Bayesian network meta-analysis2023The Journal of allergy and clinical immunology
Chronic rhinosinusitis with nasal polyps (CRSwNP) treated with omalizumab, dupilumab, or mepolizumab: A systematic review of the current knowledge towards an attempt to compare agents' efficacy2023International forum of allergy & rhinology
Smell improvement in chronic rhinosinusitis with nasal polyps with monoclonal antibodies: a systematic review2023Journal of investigational allergology & clinical immunology
Systemic and Local Medical or Surgical Therapies for Ear, Nose and/or Throat Manifestations in ANCA-Associated Vasculitis: A Systematic Literature Review2023Journal of clinical medicine
The role of anti-eosinophilic therapies in eosinophilic granulomatosis with polyangiitis: a systematic review2023Rheumatology international
Comparative efficacy and safety of tezepelumab and other biologics in patients with inadequately controlled asthma according to thresholds of type 2 inflammatory biomarkers: a systematic review and network meta-analysis.2022Cells
Anti‐IL5 therapies for asthma.2022Cochrane Database of Systematic Reviews
Comparative efficacy of mepolizumab, benralizumab, and dupilumab in eosinophilic asthma: A Bayesian network meta-analysis.2022The Journal of Allergy and Clinical Immunology
Which Is the Best Biologic for Nasal Polyps: Dupilumab, Omalizumab, or Mepolizumab? A Network Meta-Analysis2022International archives of allergy and immunology
Comparative efficacy and safety of monoclonal antibodies and aspirin desensitization for chronic rhinosinusitis with nasal polyposis: A systematic review and network meta-analysis2022The Journal of allergy and clinical immunology
Adverse events of biological therapy in chronic rhinosinusitis with nasal polyps: A systematic review2022American journal of otolaryngology
Efficacy and Safety of Anti-Interleukin-5 Therapies in Chronic Rhinosinusitis with Nasal Polyps: A Systematic Review and Meta-Analysis of Randomized Controlled Trials2022International archives of allergy and immunology
Assessment report: Nucala. 2021EMA
Mepolizumab in hypereosinophilic syndrome: a systematic review and meta-analysis. 2021Clinics
Real-life effectiveness of mepolizumab in severe asthma: a systematic literature review.2021Journal of Asthma
Real-world effectiveness of mepolizumab in severe eosinophilic asthma: a systematic review and meta-analysis.2021Clinical Therapeutics
Biologics for chronic rhinosinusitis.2021Cochrane Database of Systematic Reviews
Monoclonal antibodies targeting il-5 or il-5rα in eosinophilic chronic obstructive pulmonary disease: a systematic review and meta-analysis.2021Frontiers in Pharmacology
Treatment of lymphocyte-variant hypereosinophilic syndrome (L-HES): what to consider after confirming the elusive diagnosis2021British journal of haematology
Matching-adjusted comparison of oral corticosteroid reduction in asthma: Systematic review of biologics.2020Clinical and Experimental Allergy: Journal of the British Society for Allergy and Clinical Immunology
Anti-cytokine targeted therapies for ANCA-associated vasculitis2020The Cochrane database of systematic reviews
The role of biologics in chronic rhinosinusitis: a systematic review2020International forum of allergy & rhinology
Monoclonal antibodies in type 2 asthma: a systematic review and network meta-analysis.2019Respiratory Research
Reslizumab and mepolizumab for moderate-to-severe poorly controlled asthma: an indirect comparison meta-analysis2019Immunotherapy
Safety and Efficacy of Mepolizumab in Patients with Eosinophilic Granulomatosis with Polyangiitis2019Pulmonary medicine
Efficacy, adverse events, and inter-drug comparison of mepolizumab and reslizumab anti-IL-5 treatments of severe asthma - a systematic review and meta-analysis2018European Clinical Respiratory Journal
Monoclonal antibodies for the treatment of chronic rhinosinusitis with nasal polyposis: a systematic review2018Rhinology

Clinical Practice Guidelines